uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QURE uniQure NV

Post-Mkt 03-04 16:41:22 EST

9.04

+0.01

+0.11%

盘后9.05

+0.01+0.11%

16:29 EST

High9.49	Low9.00	Vol3.38M
Open9.08	D1 Closing9.03	Amplitude5.39%
Mkt Cap563.12M	Tradable Cap367.35M	Total Shares62.29M
T/O30.87M	T/O Rate8.31%	Tradable Shares40.64M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"QURE","market":"US","secType":"STK","nameCN":"uniQure NV","latestPrice":9.04,"timestamp":1772658000000,"preClose":9.03,"halted":0,"volume":3377222,"hourTrading":{"tag":"盘后","latestPrice":9.05,"preClose":9.04,"latestTime":"16:29 EST","volume":11792,"amount":106476.30030399999,"timestamp":1772659783977,"change":0.01,"changeRate":0.001106,"amplitude":0.016593},"delay":0,"changeRate":0.0011074197120708514,"floatShares":40636300,"shares":62291663,"eps":-3.46024,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"03-04 16:41:22 EST","open":9.08,"high":9.4865,"low":9,"amount":30868560.704152,"amplitude":0.053876,"askPrice":9.3,"askSize":20,"bidPrice":8.95,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-3.46024,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772672400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1391576400000,"exchange":"NASDAQ","adjPreClose":9.03,"preHourTrading":{"tag":"盘前","latestPrice":8.9613,"preClose":9.03,"latestTime":"09:29 EST","volume":42541,"amount":381318.04022200004,"timestamp":1772634581267,"change":-0.0687,"changeRate":-0.007608,"amplitude":0.035437},"postHourTrading":{"tag":"盘后","latestPrice":9.05,"preClose":9.04,"latestTime":"16:29 EST","volume":11792,"amount":106476.30030399999,"timestamp":1772659783977,"change":0.01,"changeRate":0.001106,"amplitude":0.016593},"volumeRatio":0.322041,"impliedVol":0.9239,"impliedVolPercentile":0.4183},"requestUrl":"/m/hq/s/QURE","defaultTab":"news","newsList":[{"id":"2616555977","title":"What's Going On With uniQure Stock Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2616555977","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616555977?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:58","pubTimestamp":1772636280,"startTime":"0","endTime":"0","summary":"QURE hits bearish territory after FDA trial news. With shares near 52-week lows, see the key support and resistance levels to watch.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/04/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/04/FDA_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51035933/whats-going-on-with-uniqure-stock-wednesday-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4217","LU0109394709.USD","LU0889565916.HKD","SMA","QURE","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2616807559","title":"Berger Montague alerts uniQure investors to class action lead plaintiff deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616807559","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616807559?lang=en_us&edition=fundamental","pubTime":"2026-03-04 22:37","pubTimestamp":1772635038,"startTime":"0","endTime":"0","summary":"A class action lawsuit has been filed against uniQure NV on behalf of investors who bought or acquired its securities between September 24, 2025 and October 31, 2025. The suit alleges the company misled investors about the design and progress of its AMT-130 pivotal study for Huntington’s disease and the likelihood of accelerated approval, before later disclosing that the FDA did not accept Phase I/II data as sufficient for a BLA submission. Investors seeking appointment as lead plaintiff must file by April 13, 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL2gv0vx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","LU0109394709.USD","QURE","LU0889565916.HKD"],"gpt_icon":0},{"id":"2616054183","title":"Rosen Law Firm Urges uniQure Investors to Meet April 13 Lead Plaintiff Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616054183","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616054183?lang=en_us&edition=fundamental","pubTime":"2026-03-04 08:36","pubTimestamp":1772584577,"startTime":"0","endTime":"0","summary":"A securities class action has been filed involving uniQure NV on behalf of investors who bought ordinary shares between September 24, 2025 and October 31, 2025. The suit alleges the company misrepresented or failed to disclose issues around FDA approval of its pivotal study design for a Huntington’s disease program and the likelihood of delays to its biologics license application timeline, which allegedly harmed investors when the information emerged. An April 13, 2026 deadline has been set for motions to seek appointment as lead plaintiff.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLbX42TZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","QURE"],"gpt_icon":0},{"id":"2616532671","title":"These Analysts Cut Their Forecasts On uniQure Following Q4 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2616532671","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616532671?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:34","pubTimestamp":1772548445,"startTime":"0","endTime":"0","summary":"uniQure (NASDAQ:QURE) reported positive Q4 results, but FDA advised against using data for market application of AMT-130. Stock down 13.3%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51000156/these-analysts-cut-their-forecasts-on-uniqure-following-q4-results","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0109394709.USD","LU0889565916.HKD","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2616332814","title":"Chardan Cuts Price Target on uniQure to $16 From $53, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332814","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332814?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:16","pubTimestamp":1772543760,"startTime":"0","endTime":"0","summary":"uniQure (QURE) has an average rating of overweight and mean price target of $31.75, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","QURE"],"gpt_icon":0},{"id":"2616282473","title":"uniQure Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2616282473","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616282473?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:10","pubTimestamp":1772543400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 08:10 ET (13:10 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0320765992.SGD","BK4139","LU0889565916.HKD","QURE"],"gpt_icon":0},{"id":"2616340023","title":"uniQure price target lowered to $16 from $53 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340023?lang=en_us&edition=fundamental","pubTime":"2026-03-03 20:55","pubTimestamp":1772542535,"startTime":"0","endTime":"0","summary":"Chardan lowered the firm’s price target on uniQure (QURE) to $16 from $53 and keeps a Buy rating on the shares after the company held a Type A meet...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-lowered-to-16-from-53-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-price-target-lowered-to-16-from-53-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","LU0109394709.USD","BK4139","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2616344967","title":"Uniqure Nv : Mizuho Cuts to Neutral From Outperform; Cuts Target Price to $12 From $33","url":"https://stock-news.laohu8.com/highlight/detail?id=2616344967","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616344967?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:51","pubTimestamp":1772538675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0VZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU0320765992.SGD","QURE","LU0109394709.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2616341775","title":"Uniqure Nv : Wells Fargo Cuts to Equal Weight From Overweight; Cuts Target Price to $15 From $60","url":"https://stock-news.laohu8.com/highlight/detail?id=2616341775","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616341775?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:38","pubTimestamp":1772537919,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nFWN3ZR0VG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["QURE","LU0320765992.SGD","LU0109394709.USD","LU0889565916.HKD","BK4139"],"gpt_icon":0},{"id":"2616345837","title":"Barclays Reaffirms Their Hold Rating on uniQure (QURE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616345837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616345837?lang=en_us&edition=fundamental","pubTime":"2026-03-03 17:45","pubTimestamp":1772531140,"startTime":"0","endTime":"0","summary":"Barclays analyst Eliana Merle maintained a Hold rating on uniQure today and set a price target of $31.00. According to TipRanks, Merle is a 3-star ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-hold-rating-on-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-hold-rating-on-uniqure-qure-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE"],"gpt_icon":0},{"id":"2616331344","title":"uniQure Faces 2026 Shift to Dutch Large Company Regime, Curbing Direct Shareholder Control Over Board Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331344","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331344?lang=en_us&edition=fundamental","pubTime":"2026-03-03 14:01","pubTimestamp":1772517684,"startTime":"0","endTime":"0","summary":"uniQure N.V. (QURE) has disclosed a new risk, in the Economy & Political Environment category. uniQure N.V. is expected to fall under the Dutch lar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/uniqure-faces-2026-shift-to-dutch-large-company-regime-curbing-direct-shareholder-control-over-board-appointments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/uniqure-faces-2026-shift-to-dutch-large-company-regime-curbing-direct-shareholder-control-over-board-appointments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","QURE","BK4139","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2616939047","title":"uniQure (QURE) was downgraded to a Hold Rating at Mizuho Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2616939047","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616939047?lang=en_us&edition=fundamental","pubTime":"2026-03-03 13:06","pubTimestamp":1772514398,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Uy Ear downgraded uniQure to a Hold yesterday and set a price target of $12.00. The company’s shares closed yesterday at ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/uniqure-qure-was-downgraded-to-a-hold-rating-at-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/uniqure-qure-was-downgraded-to-a-hold-rating-at-mizuho-securities-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QURE","MFG"],"gpt_icon":0},{"id":"2616339926","title":"UniQure (QURE) Posts Q4 Loss Of US$37.1m Reinforcing Profitability Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339926","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339926?lang=en_us&edition=fundamental","pubTime":"2026-03-03 10:22","pubTimestamp":1772504562,"startTime":"0","endTime":"0","summary":"uniQure (QURE) has just wrapped up FY 2025 with fourth quarter revenue of US$5.6 million and a basic EPS loss of US$0.59, as net income excluding extra items came in at a loss of US$37.1 million. Over recent quarters, the company has seen revenue move between US$1.6 million and US$5.6 million while basic EPS ranged from a loss of US$0.59 to a loss of US$1.38. This gives investors a clear picture of a business that is still in heavy investment mode rather than focused on near term...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-qure/uniqure/news/uniqure-qure-posts-q4-loss-of-us371m-reinforcing-profitabili","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139","QURE"],"gpt_icon":0},{"id":"1126382027","title":"FDA Mandates Phase III Trial for uniQure's Huntington's Disease Gene Therapy, Blocking Market Approval and Sending Shares Down 33%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126382027","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126382027?lang=en_us&edition=fundamental","pubTime":"2026-03-03 09:56","pubTimestamp":1772502995,"startTime":"0","endTime":"0","summary":"Gene therapy firm uniQure NV (QURE.US) saw its hopes for accelerated approval of its Huntington's disease candidate AMT-130 by the U.S. FDA dashed recently. The FDA has clearly informed the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","QURE","III","LU0109394709.USD","BK4134","BK4139","LU0320765992.SGD"],"gpt_icon":0},{"id":"2616398411","title":"Rosen Law Firm Sets April 13 Lead Plaintiff Deadline in uniQure Securities Class Action","url":"https://stock-news.laohu8.com/highlight/detail?id=2616398411","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616398411?lang=en_us&edition=fundamental","pubTime":"2026-03-03 08:31","pubTimestamp":1772497878,"startTime":"0","endTime":"0","summary":"A securities class action has been filed against uniQure NV in the United States on behalf of investors who bought the company’s ordinary shares between Sept. 24, 2025 and Oct. 31, 2025. The suit alleges the company misrepresented or failed to disclose that the FDA had not fully approved aspects of the design and data comparisons used in its Huntington’s disease pivotal study and downplayed the likelihood it would need additional studies that could delay its biologics license application timeline. An April 13, 2026 deadline has been set for investors seeking to be appointed lead plaintiff.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDLcW7Yd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","BK4139","LU0320765992.SGD","QURE"],"gpt_icon":0},{"id":"2616398532","title":"uniQure downgraded to Equal Weight from Overweight at Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2616398532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616398532?lang=en_us&edition=fundamental","pubTime":"2026-03-03 08:15","pubTimestamp":1772496910,"startTime":"0","endTime":"0","summary":"Wells Fargo downgraded uniQure (QURE) to Equal Weight from Overweight with a price target of $15, down from $60 after the company said the FDA “str...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-downgraded-to-equal-weight-from-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-downgraded-to-equal-weight-from-overweight-at-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0310800379.SGD","LU0128525929.USD","LU0130517989.USD","LU0320765489.SGD","LU0211328371.USD","LU0477156953.USD","LU1791807156.HKD","LU2361044865.SGD","LU0154236417.USD","IE0002270589.USD","LU1201861249.SGD","LU0289960550.SGD","LU0942090050.USD","LU0320765992.SGD","LU1074936037.SGD","LU0175139822.USD","LU0640476718.USD","LU0029864427.USD","LU1894683348.USD","LU0128525689.USD","LU0048573561.USD","LU0149725797.USD","LU0070302665.USD","LU2236285917.USD","LU2361044949.HKD","LU0648001328.SGD","LU0971096721.USD","BK4207","LU0256863811.USD","LU0868494708.USD","LU0683600562.USD","BK4501","LU0109394709.USD","LU1035773651.USD","LU1069347547.HKD","QURE","LU0310799852.SGD","IE000M9KFDE8.USD","LU0251142724.SGD","LU1668664300.SGD","LU0130102774.USD","LU1280957306.USD","LU1894683264.USD","LU1506573853.SGD","LU0072461881.USD","LU0310800965.SGD","LU0742534661.SGD","LU1267930573.SGD","IE00B19Z3581.USD","LU0251131958.USD"],"gpt_icon":0},{"id":"2616536317","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2616536317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616536317?lang=en_us&edition=fundamental","pubTime":"2026-03-03 03:31","pubTimestamp":1772479865,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics  said late Friday it paused its phase 3 trial of ARD-101 for hyperphagia in patients with Prader-Willi Syndrome after reversible cardiac observations at above target therapeutic doses were found during routine safety monitoring in a healthy volunteer study.RBC downgraded the stock to sector perform from outperform. Other downgrades include HC Wainwright to neutral from buy.Shares sank 56% Monday, with intraday trading volume of over 2.24 million against a daily average of about 191,000.uniQure  shares tumbled 32% after the US Food and Drug Administration said data from the company's phase 1/2 trials was not sufficient to provide the primary evidence of effectiveness needed to support a marketing application for AMT-130, an investigational gene therapy for Huntington's disease.More than 13.7 million shares traded intraday, compared with a daily average of about 2.64 million.Price: 5.46, Change: -7.03, Percent Change: -56.29","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","QURE","AARD","BK4139"],"gpt_icon":0},{"id":"2616368056","title":"uniQure Raised to Neutral From Overweight by Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2616368056","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616368056?lang=en_us&edition=fundamental","pubTime":"2026-03-03 03:08","pubTimestamp":1772478480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QURE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 14:08 ET (19:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QURE","LU0320765992.SGD","BK4139","LU0889565916.HKD","LU0109394709.USD"],"gpt_icon":0},{"id":"2616935288","title":"uniQure downgraded at RBC after ‘disappointing’ Huntington’s update","url":"https://stock-news.laohu8.com/highlight/detail?id=2616935288","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616935288?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:47","pubTimestamp":1772470022,"startTime":"0","endTime":"0","summary":"As previously reported, RBC Capital analyst Luca Issi downgraded uniQure (QURE) to Sector Perform from Outperform with a price target of $11, down ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/uniqure-downgraded-at-rbc-after-disappointing-huntingtons-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/uniqure-downgraded-at-rbc-after-disappointing-huntingtons-update-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765992.SGD","LU0128525929.USD","LU0708994859.HKD","LU0889565916.HKD","BK4207","BK4139","LU1267930573.SGD","LU0029864427.USD","LU0109394709.USD","LU0310800379.SGD","QURE"],"gpt_icon":0},{"id":"2616354840","title":"Uniqure Nv : RBC Cuts to Sector Perform From Outperform; Cuts Target Price to $11 From $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2616354840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616354840?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:32","pubTimestamp":1772469155,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZQ187:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0109394709.USD","QURE","BK4139","LU0889565916.HKD","LU0320765992.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.uniqure.com","stockEarnings":[{"period":"1week","weight":-0.6242},{"period":"1month","weight":-0.6026},{"period":"3month","weight":-0.6456},{"period":"6month","weight":-0.4907},{"period":"1year","weight":-0.1716},{"period":"ytd","weight":-0.6226}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0168},{"period":"3month","weight":-0.0052},{"period":"6month","weight":0.0481},{"period":"1year","weight":0.1654},{"period":"ytd","weight":-0.0023}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.009035},{"month":2,"riseRate":0.5,"avgChangeRate":0.032875},{"month":3,"riseRate":0.230769,"avgChangeRate":-0.082442},{"month":4,"riseRate":0.416667,"avgChangeRate":0.018299},{"month":5,"riseRate":0.666667,"avgChangeRate":0.042965},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.009437},{"month":7,"riseRate":0.25,"avgChangeRate":0.033059},{"month":8,"riseRate":0.5,"avgChangeRate":0.005984},{"month":9,"riseRate":0.25,"avgChangeRate":0.122705},{"month":10,"riseRate":0.5,"avgChangeRate":0.060394},{"month":11,"riseRate":0.75,"avgChangeRate":0.0616},{"month":12,"riseRate":0.25,"avgChangeRate":0.125134}],"exchange":"NASDAQ","name":"uniQure NV","nameEN":"uniQure NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"uniQure NV,QURE,uniQure NV股票,uniQure NV股票老虎,uniQure NV股票老虎国际,uniQure NV行情,uniQure NV股票行情,uniQure NV股价,uniQure NV股市,uniQure NV股票价格,uniQure NV股票交易,uniQure NV股票购买,uniQure NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"uniQure NV(QURE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest uniQure NV(QURE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}